At a glance
ClinicalIndex Comparison RecordN/ACompleted· 375 enrolled
Drug / intervention
Patient Compliancebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment Of Statin Treatment Compliance In Dyslipidemia Patients: An Observational Study
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted May 7, 2008·Updated Feb 21, 2021
In Brief
An observational study evaluating Patient Compliance for Dyslipidemia. Completed, enrolled 375 participants across 5 sites.
Detailed Summary
The purpose of the study is to show the compliance rates of the patients to statin treatment and the reasons of non-compliance.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesTurkey (Türkiye)
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedMay 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedMay 7, 2008
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.2 years ago
Interventions
Patient Compliancebehavioral
Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.